TORC1/2 Inhibitor MLN0128 and Bevacizumab in Treating Patients With Recurrent Glioblastoma or Advanced Solid Tumors | ClinicalTrials HQ

Ask about research services

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
TORC1/2 Inhibitor MLN0128 and Bevacizumab in Treating Patients With Recurrent Glioblastoma or Advanced Solid Tumors	Adnexal Diseases, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Urogenital Diseases, Urogenital Neoplasms, adult glioblastoma, astrocytoma (excluding glioblastoma), endocrine system disorder, endometrial clear cell adenocarcinoma, endometrial serous adenocarcinoma, epithelial neoplasm, fallopian tube disorder, fallopian tube neoplasm, female reproductive system disorder, female reproductive system neoplasm, glioblastoma, glioma, gonadal disorder, malignant endocrine neoplasm, neoplasm, neuroepithelial neoplasm, ovarian cancer, ovarian clear cell cystadenocarcinoma, ovarian disorder, ovarian endometrioid adenocarcinoma, ovarian mucinous cystadenocarcinoma, ovarian serous cystadenocarcinoma, primitive neuroectodermal tumor	Active, not recruiting	Phase 1	2026-08-28		NCT02142803

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
National Cancer Institute (NCI)	3015

3 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Dana-Farber Cancer Institute	Boston	United States	626
Massachusetts General Hospital	Charlestown	United States	22
Ohio State University Comprehensive Cancer Center	Columbus	United States	548